A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial

被引：0

作者：

Gerardo Rosati

Chiara Alessandra Cella

Luigi Cavanna

Carla Codecà

Michele Prisciandaro

Stefania Mosconi

Giovanna Luchena

Nicola Silvestris

Ilaria Bernardini

Rossana Casaretti

Federica Zoratto

Domenico Amoroso

Andrea Ciarlo

Sandro Barni

Stefano Cascinu

Cristina Davite

Alessandro Di Sanzo

Alessia Casolaro

Domenico Bilancia

Roberto Labianca

机构：

[1] Azienda Ospedaliera San Carlo,UOC di Oncologia Medica

[2] IEO,Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors

[3] European Institute of Oncology IRCCS,Dipartimento di Oncologia

[4] Azienda USL,Ematologia

[5] Ospedale di Piacenza,U.O. Oncologia Medica, ASST Santi Paolo e Carlo

[6] Presidio Ospedaliero San Paolo,Divisione di Oncologia Medica

[7] Fondazione IRCCS Istituto Nazionale dei Tumori,Dipartimento di Oncologia ed Ematologia

[8] ASST Papa Giovanni XXIII,U.O. Oncologia Medica

[9] Ospedale Sant’Anna,U.O.C. Oncologia Medica

[10] IRCCS Istituto Tumori Giovanni Paolo II,Dipartimento di Oncologia

[11] Ospedale Ramazzini,Department of Abdominal Oncology

[12] Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”,U.O.C. Oncologia Medica

[13] Ospedale Santa Maria Goretti,Ospedale Versilia

[14] Azienda USL Toscana Nordovest (ATNO),U.O. Oncologia Medica

[15] AUSL Toscana Centro,U.O. Oncologia Medica, ASST Bergamo Ovest

[16] Ospedale di Prato,Unità di Medicina Oncologica

[17] Ospedale di Treviglio-Caravaggio,Global Clinical Development

[18] IRCCS Ospedale San Raffaele,undefined

[19] Nerviano Medical Sciences,undefined

来源：

Gastric Cancer | 2022年 / 25卷

关键词：

Advanced gastric cancer; EOX; LEGA trial; Low-TOX; Triplet regimen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：783 / 793

页数：10

共 50 条

[1] A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
Rosati, Gerardo
Cella, Chiara Alessandra
Cavanna, Luigi
Codeca, Carla
Prisciandaro, Michele
Mosconi, Stefania
Luchena, Giovanna
Silvestris, Nicola
Bernardini, Ilaria
Casaretti, Rossana
Zoratto, Federica
Amoroso, Domenico
Ciarlo, Andrea
Barni, Sandro
Cascinu, Stefano
Davite, Cristina
Di Sanzo, Alessandro
Casolaro, Alessia
Bilancia, Domenico
Labianca, Roberto
[J]. GASTRIC CANCER, 2022, 25 (04) : 783 - 793
[2] Comparison of efficacy of aspirin plus epirubicin, oxaliplatin, and capecitabine versus epirubicin, oxaliplatin, and capecitabine alone in patients with locally advanced and metastatic gastric cancer: A randomized clinical trial
Jafa, Esha
Dubashi, Biswajit
Kayal, Smita
Kate, Vikram
Ganesh, Rajesh Nachiappa
Sunitha, V. C.
Charles, L.
Nisha, Yadav
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX)
Pluschnig, U.
Zacherl, J.
Schoppmann, S.
Raderer, M.
Prager, G.
Bartsch, R.
Ba-Ssalamah, A.
Lamm, W.
Zielinski, C.
Hejna, M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[4] Neoadjuvant chemotheraphy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis
Pluschnig, U.
Zacherl, J.
Schoppmann, S.
Raderer, M.
Prager, G.
Bartsch, R.
Ba-Ssalamah, A.
Lamm, W.
Zielinski, C.
Hejna, M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma
Petersen, Peter C.
Petersen, Lone N.
Vogelius, Ivan
Bjerregaard, Jon K.
Baeksgaard, Lene
[J]. ACTA ONCOLOGICA, 2021, 60 (07) : 948 - 953
[6] Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
Wang, Yan
Zhuang, Rong-yuan
Yu, Yi-yi
Yu, Shan
Hou, Jun
Ji, Yuan
Sun, Yi-hong
Shen, Kun-tang
Shen, Zhen-bin
Liu, Feng-lin
Zhao, Nai-qing
Liu, Tian-shu
[J]. ONCOTARGET, 2016, 7 (46) : 76298 - 76307
[7] Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
Wang, Yan
Yu, Yiyi
Zhuang, Rongyuan
Yu, Shan
Hou, Jun
Ji, Yuan
Sun, Yihong
Shen, Kuntang
Shen, Zhenbin
Liu, Fenglin
Zhao, Naiqing
Liu, Tianshu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial
Tian, Yuan
Yang, Peigang
Guo, Honghai
Liu, Yang
Zhang, Ze
Ding, Pingan
Zheng, Tao
Deng, Huiyan
Ma, Wenqian
Li, Yong
Fan, Liqiao
Zhang, Zhidong
Wang, Dong
Zhao, Xuefeng
Tan, Bibo
Liu, Yu
Zhao, Qun
[J]. INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4000 - 4008
[9] Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
Guo, Weijian
Zhu, Xiaodong
Huang, Mingzhu
Wang, Yusheng
Chen, Zhiyu
Feng, Wanjing
He, Yifu
Zhang, Xiaowei
Liu, Xin
Wang, Chenchen
Zhang, Wen
Ying, Jieer
Wu, Jun
Yang, Lei
Qin, Yanru
Zhao, Xiaoying
Li, Wenhua
Zhang, Zhe
Qiu, Lixin
Wang, XiaoFeng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Comparison of efficacy and safety of capecitabine and oxaliplatin (CAPOX) with epirubicin, oxaliplatin plus capecitabine (EOX) as first line treatment for advanced gastric cancer (AGC), a randomized clinical study
Kayal, Smita
Pani, Chinmaya Kumar
Biswajit, Dubashi
Verma, Surendrakumar
Sistla, Sarath Chandra
Cyriac, Sunu Lazar
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →